China BlueChemical Ltd

China BlueChemical Ltd maintains a conservative capital structure with a debt-to-equity ratio of 0.11 and a strong current ratio of 4.62, indicating ample short-term liquidity to meet obligations. The company holds CNY 7.37 billion in total equity against CNY 6.01 billion in total liabilities, with long-term debt standing at CNY 2.11 billion. Despite the strong current ratio, the risk assessment flags medium liquidity risk and notes that net cash is negative after subtracting total debt, suggesting reliance on operating cash flows for debt servicing. The firm generated CNY 1.38 billion in operating cash flow and CNY 774 million in free cash flow, supporting its ability to manage its balance sheet without immediate refinancing pressure.

Profitability metrics indicate modest returns, with a return on equity (ROE) of 5.17% and a return on assets (ROA) of 3.92%. The company reported net income of CNY 974 million on revenue of CNY 12.03 billion, resulting in a net margin of approximately 8.1%. The gross profit of CNY 1.57 billion suggests a gross margin of roughly 13%, which is typical for commodity chemical producers facing cyclical input cost pressures. The operating income of CNY 957 million reflects disciplined cost management, though the low ROE suggests limited leverage of equity to generate superior returns compared to higher-margin specialty chemical peers.

Revenue concentration and segment details are not explicitly provided in the available data, limiting the ability to assess specific product mix risks. However, the company’s classification within the broader chemicals industry implies exposure to global commodity cycles and raw material price volatility. The absence of detailed geographic or segment breakdowns in the current snapshot prevents a granular analysis of regional demand drivers or customer concentration risks, necessitating reliance on industry-wide trends for context.

The growth trajectory is difficult to assess from the single-period financial snapshot provided. With a market capitalization of CNY 9.40 billion and an enterprise value-to-revenue multiple of 0.9, the company is valued at a discount to its sales, which may reflect market skepticism about future growth prospects or cyclical downturns in the chemical sector. The price-to-earnings ratio of 9.65 and price-to-book ratio of 0.5 suggest the market is pricing in limited growth expectations, potentially offering a margin of safety if operational efficiency improves or commodity prices stabilize.

Risk factors include medium liquidity risk and the flag of negative net cash, which could constrain strategic flexibility during periods of tight credit markets. Dilution risk is assessed as low, with basic and diluted shares outstanding both at 4.61 billion, indicating no significant options or convertible securities currently impacting share count. The company’s low debt-to-equity ratio mitigates credit risk, but the negative net cash position requires monitoring to ensure operating cash flows remain sufficient to cover debt maturities and capital expenditures.

Recent analyst sentiment is strongly positive, with a mean recommendation of 1.00 (strong buy) and a mean price target of CNY 3.58, implying significant upside from the current market price of CNY 2.04. The high price target of CNY 4.05 and low of CNY 3.10 suggest a consensus view that the current valuation is depressed. This bullish stance contrasts with the conservative financial metrics, potentially indicating expectations for a cyclical recovery or operational improvements not yet reflected in the latest financial snapshot.

Analysts project 45.3% upside to a mean target price of 3.575, reflecting strong buy consensus.

Free cash flow surged 217.2% year-over-year to 774 million CNY in the latest fiscal period.

Debt-to-equity ratio of 0.11 is well below the cohort median of 0.40, suggesting low financial leverage.

Revenue contracted at a 2.6% annual rate over four years, indicating shrinking top-line growth.

The company faces medium liquidity risk, which could constrain short-term financial flexibility.

Revenue ¥12.03B, +0,7% YoY; Operating income −14,6% YoY.

• ▍Revenue ¥12.03B, +0,7% YoY
• ▍Operating income −14,6% YoY
• ▍Net income −9,0% YoY
• ▍Free cash flow +217,2% YoY
• ▍Net margin 8.1%

Revenue ¥11.95B, −8,0% YoY; Operating income −52,1% YoY.

• ▍Revenue ¥11.95B, −8,0% YoY
• ▍Operating income −52,1% YoY
• ▍Net income −55,0% YoY
• ▍Free cash flow −82,9% YoY
• ▍Net margin 9.0%

Revenue ¥12.99B, −9,0% YoY; Operating income +18,2% YoY.

• ▍Revenue ¥12.99B, −9,0% YoY
• ▍Operating income +18,2% YoY
• ▍Net income +45,0% YoY
• ▍Free cash flow +388,5% YoY
• ▍Net margin 18.3%

Revenue ¥14.28B, +6,6% YoY; Operating income −14,5% YoY.

• ▍Revenue ¥14.28B, +6,6% YoY
• ▍Operating income −14,5% YoY
• ▍Net income +9,7% YoY
• ▍Free cash flow −60,1% YoY
• ▍Net margin 11.5%

Revenue ¥13.40B; Operating income ¥2.32B.

• ▍Revenue ¥13.40B
• ▍Operating income ¥2.32B
• ▍Net margin 11.2%